Recordati Industria Chimica e Farmaceutica S.p.A.

WBAG:REC Stock Report

Market Cap: €10.6b

Recordati Industria Chimica e Farmaceutica Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Rob Koremans

Chief executive officer

€2.5m

Total compensation

CEO salary percentage23.6%
CEO tenure3.1yrs
CEO ownershipn/a
Management average tenure4.4yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Koremans's remuneration changed compared to Recordati Industria Chimica e Farmaceutica's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

€423m

Jun 30 2024n/an/a

€387m

Mar 31 2024n/an/a

€389m

Dec 31 2023€2m€590k

€389m

Sep 30 2023n/an/a

€375m

Jun 30 2023n/an/a

€389m

Mar 31 2023n/an/a

€340m

Dec 31 2022€2m€590k

€312m

Sep 30 2022n/an/a

€331m

Jun 30 2022n/an/a

€330m

Mar 31 2022n/an/a

€393m

Dec 31 2021€154kn/a

€386m

Compensation vs Market: Rob's total compensation ($USD2.59M) is below average for companies of similar size in the Austrian market ($USD4.32M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Koremans (62 yo)

3.1yrs

Tenure

€2,498,000

Compensation

Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Koremans
CEO & Director3.1yrs€2.50mno data
Luigi Felice Corte
Group CFO & Executive Director5.2yrs€1.23mno data
Cathrin Petty
Executive Directorno datano datano data
Giampiero Mazza
Executive Director6yrsno datano data
Giorgio De Palma
Executive Director4.8yrsno datano data
Eugenia Litz
VP & Head of Investor Relationsless than a yearno datano data
Bibianne Bon
Group Chief Legal Officer1.8yrsno datano data
Laura Conti
Group Communications Directorno datano datano data
Gabriele Finzi
Executive VP of Corporate Development8.3yrsno datano data
Alessandra Abate
Group Chief People & Culture Officerless than a yearno datano data
Raffaele Sabia
Chief Medical Officer6yrsno datano data
Alberto Martinez
Executive Vice President of Specialty & Primary Care Business Unit4yrsno datano data

4.4yrs

Average Tenure

55yo

Average Age

Experienced Management: REC's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Koremans
CEO & Director3.1yrs€2.50mno data
Luigi Felice Corte
Group CFO & Executive Director3yrs€1.23mno data
Cathrin Petty
Executive Director6.1yrsno datano data
Giampiero Mazza
Executive Director6.1yrsno datano data
Giorgio De Palma
Executive Director4.8yrsno datano data
Andrea Recordati
Non-Executive Chairman26.8yrs€315.00kno data
Piergiorgio Peluso
Independent Non-Executive Director4.8yrs€80.00kno data
Michaela Castelli
Lead Independent Director10.8yrs€103.00kno data
Elisa Corghi
Independent Director3yrs€90.00kno data
Antonio Santi
Chairman of Statutory Auditor Board7.8yrsno datano data
Joanna Le Couilliard
Independent Non-Executive Director5.9yrs€85.00kno data
Guido Guidi
Non-Executive Vice Chairman4.8yrs€90.00kno data

5.3yrs

Average Tenure

54.5yo

Average Age

Experienced Board: REC's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 05:51
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paola SagliettiBanca Akros S.p.A. (ESN)
Charles Pitman-KingBarclays
Vincent MeunierBNP Paribas Exane